

## Published US Pilot Study Highlights Clinical Experience with CERAMENT® G in Trauma

**BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces the first publication of a US clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in trauma. Published in OTA International, the study offers practical, real-world insights for clinicians adopting CERAMENT G in trauma care.**

The technique used in this pilot study, conducted at HCA Florida Kendall Hospital, included debridement,

Flow-FX™ 2-CAN® delivery of CERAMENT G, with local antibiotic elution, and when required, stable fixation. Patients with either fracture related infections or osteomyelitis, were followed for an average of 14.4 months. Across all cases, the authors reported no recurrence of infection, no major complications or amputations and radiographic union.

“This first US-based publication from a single Level-1 trauma center, evaluating CERAMENT G provides a clear, technique-driven guidance for surgeons managing challenging cases after trauma. Despite its pilot scale, it underscores the effectiveness of CERAMENT G in intramedullary use, combining infection control with reliable bone healing. It further strengthens our momentum in the US trauma market by highlighting a technique well aligned with American surgical practice,” said Torbjörn Sköld, CEO of BONESUPPORT.

### For more information contact:

---

BONESUPPORT AB  
Torbjörn Sköld, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46 (0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

Cord Communications  
Charlotte Stjerngren  
+46 (0) 708 76 87 87  
[charlotte.stjerngren@cordcom.se](mailto:charlotte.stjerngren@cordcom.se)  
[www.cordcom.se](http://www.cordcom.se)

Press Release  
27 February 2026 14:45:00 CET



## About BONESUPPORT™

---

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

## Attachments

---

[Published US Pilot Study Highlights Clinical Experience with CERAMENT® G in Trauma](#)